Tempting Volatility: TPST Stock Shows Potential for Growth Despite Risks

Fundamental Analysis

Tempest Therapeutics, Inc., under the ticker symbol TPST, currently has a market capitalization of approximately $88.40 million. The closing price as of October 19, 2023 was $6.07, with a daily change of $0.22, a positive 3.76% return. The stock witnessed a significant intraday swing, with a low of $5.12 and closing near the day's high of $6.76. However, the stock remains quite a distance from its year high of $9.77, indicating potential room for growth. The year low looks largely irrelevant at this point, having reached $0.17, considering the stock's current price.

The stock's trading volume stands at 15.65 million, nearly double its average volume of 7.99 million, indicating higher investor interest and increased trading activity.

The relatively high RSI of 69 suggests that the stock is approaching overbought territory, usually a caution sign for investors. The MACD (3-month) at 0.66 indicates a short-term bullish price trend.

Notably, the company's EPS stands at a negative $3.89, suggesting that the company is not currently profitable. The negative PE of -1.56 corroborates this data.

However, there seems to be some approval from analysts, as the consensus based on the given data appears to lean towards a "Buy" recommendation, indicating professional optimism towards the stock’s performance.

While there has been significant price volatility recently, the most recent news reveals no fundamental change in the company's operations to justify such large gains. The discounted cash flow (DCF) stands at $8.77, suggesting the stock may be undervalued.

Technical Analysis

Tempest Therapeutics has recently been trading well above its 50-day moving average ($1.17) and 200-day moving average ($1.55), indicating a strong upward trend and strong momentum for TPST.

The ATR (Average True Range, a measure of volatility) stands quite high at 21.31, revealing the stock to be highly volatile. This, coupled with already high trading volume, suggests potential for sudden price moves.

The current data provide the stock's support and resistance levels. The support level of $5.85 is near its current price, indicating potential for a bounce back if the price drops to near this level. However, the stock's resistance level is $6.74, which, if crossed with significant volume, could lead to further upward price action. The provided stop-loss level is $5.76.

Predicted Performance

Given the overall bullish sentiment and the upward momentum reflected by the indicators, the stock might maintain its bullish run during the next trading day on October 20, 2023, as well as over the subsequent week. However, the high RSI and ATR may suggest caution. Given the volatility, accurate prediction is challenging.

Final Evaluation

Based on the review of the available data and considering both fundamental and technical analysis, TPST appears to be a volatile, high-risk stock.

While the company is not currently profitable, the market seems to hold a generally positive view of its future prospects, causing its share price to surge. The recent wild fluctuations should warrant caution among more conservative investors since price surges without accompanying strong fundamentals sometimes foreshadow a correction.

Given the relatively high DCF valuation and the high level of analyst support, Tempest Therapeutics can be considered a potential "Buy" for risk-tolerant investors who believe in its future profitability and can stomach the possible swings.

It may be prudent for investors to keep a close watch on this stock and consider setting stop-loss orders to protect their investments. However, as the company’s earnings announcement on November 6, 2023, is approaching, this may provide more clarity regarding the company's operational performance and profitability. This upcoming event could affect the final evaluation significantly.